. Author manuscript; available in PMC: 2013 Sep 1.

Published in final edited form as: J Affect Disord. 2012 Mar 2;140(1):57–65. doi: 10.1016/j.jad.2012.01.031

Table 1.

Placebo-controlled and comparator trials included in meta-analysis of antidepressant response rates.

Placebo-controlled studies
Author	Medication	Duration	Outcome measure	Response rate	Completer sample
Byerley et al. (1988)	Fluoxetine	6	CGI	43^a	.65
	Imipramine			.41^a	.54
	Placebo			.13	.10
Claghorn et al. (1992)	Paroxetine	6	CGI	.42^a	.62
	Placebo			.27	.46
Cohn et al. (1996)	Nefazodone	8	HRSD	.64^a	.79
	Imipramine			.64^a	.78
	Placebo			.36	.45
Coleman et al. (2001)	Buproprion	8	HRSD	.37	.56
	Fluoxetine			.36	.57
	Placebo			.34	.50
Detke et al. (2002a,b)	Duloxetine	9	HRSD	.45^a	.62
	Placebo			.23	.29
Detke et al. (2002a,b)	Duloxetine	9	HRSD	.50^a	.65
	Placebo			.35	.42
Dunlop et al. (1990)	Fluoxetine 20	6	HRSD	.40	.53
	Fluoxetine 40			.40	.51
	Fluoxetine 60			.35^a	.59
	Placebo			.26	.36
Golden et al. (2002)	Paroxetine CR	12	HRSD	.60^a	.74
	Paroxetine			.56	.73
	Placebo			.48	.60
Lepola et al. (2003)	Citalopram	8	MADRS	.53	.53
	Escitalopram			.64^a	.64
	Placebo			.48	.48
Mendels et al. (1993)	Venlafaxine low	6	CGI	.60	.80
	Venlafaxine med			.65	.75
	Venlafaxine high			.68	.81
	Placebo			.50	.59
Reimherr et al. (1990)	Setraline	8	HRSD	.54^a	.82
	Amitryptiline			.60^a	.83
	Placebo			.35	.52
Rickels et al. (1994)	Nefazodone	8	HRSD	.52	.69
	Imipramine			.36	.66
	Placebo			.31	.45
Rudolph et al. (1998)	Venlafaxine 75	6	HRSD	.42	.58
	Venlafaxine 225			.50^a	.66
	Venlafaxine 375			.52^a	.67
	Placebo			.30	.38
Schweizer et al. (1994)	Venlafaxine	6	HRSD	.60^a	.77
	Imipramine			.37	.60
	Placebo			.35	.47
Smith et al. (1990)	Mirtazipine	6	HRSD	.40^a	.63
	Amitriptyline			.51^a	.69
	Placebo				.48
Walczak et al. (1996)	Fluvoxamine 25	8	HRSD	.29	.42
	Fluvoxamine 50			.30	.50
	Fluvoxamine 100			.36^a	.59
	Fluvoxamine 150			.28^a	.58
	Placebo			.23	.38
Wernicke et al. (1987)	Fluoxetine 20	6	HRSD	.39^a	.53
	Fluoxetine 40			.44^a	.61
	Fluoxetine 60			.30^a	.48
	Placebo			.19	.27
Wernicke et al. (1988)	Fluoxetine 5	6	HRSD	.46^a	.54
	Fluoxetine 20			.50^a	.64
	Fluoxetine 40			.48^a	.65
	Placebo			.23	.33

Comparator studies
Author	Medication	Duration	Outcome measure	Response rate	Completer sample
Alves et al. (1999)	Venlafaxine	12	HRSD	.85	.87
	Fluoxetine			.75	.79
Baldwin et al. (1996)	Nefazodone	8	CGI	.55	.72
	Paroxetine			.61	.72
Benkert et al. (2000)	Mirtazipine	6	HRSD	.58	.62
	Paroxetine			.54	.58
Bouchard et al. (1987)	Citalopram	6	MADRS	.78	1.0
	Maprotiline			.73	.94
Chouinard et al. (1999)	Paroxetine	12	HRSD	.67	.86
	Fluoxetine			.68	.88
Christiansen et al. (1996)	Paroxetine	8	CGI	.65	.82
	Amitriptyline			.66	.84
Debus et al. (1988)	Fluoxetine	6	HRSD	.50	.57
	Trazodone			.53	.64
Fournier (1997)	Sertraline	8	HRSD	.71	.76
	Imipramine			.74	.82
Kasper et al. (2005)	Trazodone	6	HRSD	.87	.96
	Paroxetine			.91	.91
Keegan et al. (1991)	Fluoxetine	6	HRSD	.63	.67
	Amitriptyline			.69	.84
Leinonen et al. (1999)	Mirtazipine	8	MADRS	.85	.97
	Citalopram			.88	.94
Mehtonen et al. (2000)	Venlafaxine	8	HRSD	.73^a	.83
	Sertraline			.59	.68
Moller et al. (2000)	Sertraline	6	HRSD	.51	.51
	Amitriptyline			.68	.67
Montgomery et al. (2004)	Escitalopram	8	MADRS	.77	.88
	Venlafaxine XR			.80	.87
Patris et al. (1996)	Citalopram	8	MADRS	.78	.81
	Fluoxetine			.76	.75
Perry et al. (1989)	Fluoxetine	6	HRSD	.71	.71
	Trazodone			.82	.82
Sauer et al. (2003)	Venlafaxine	6	HRSD	.40	.42
	Amitriptyline			.47	.53
Swann et al. (1997)	Phenelzine	6	HRSD	.57	.55
	Desipramine			.57	.60

Significant difference (p<0.05) reported vs. placebo or comparator group.